Clinical Trial Update: Effect of Belimumab on Antibody Titers in Primary APS Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating belimumab for reducing antibody titers in primary antiphospholipid syndrome; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Antiphospholipid Syndrome (APS) | Phase 2 | Status: RECRUITING